These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6209422)

  • 21. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
    Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
    J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential histochemical peanut agglutinin stain in benign and malignant human prostate tumors: relationship with prostatic specific antigen immunostain and nuclear DNA content.
    Janssen T; Petein M; Van Velthoven R; Van Leer P; Fourmarier M; Vanegas JP; Danguy A; Schulman C; Pasteels JL; Kiss R
    Hum Pathol; 1996 Dec; 27(12):1341-7. PubMed ID: 8958309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytostructural localization of a tumor-associated antigen.
    Howard DR; Batsakis JG
    Science; 1980 Oct; 210(4466):201-3. PubMed ID: 6997995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Tn antigen with Vicia villosa agglutinin in urinary bladder cancer: its relevance to the patient's clinical course.
    Nishiyama T; Matsumoto Y; Watanabe H; Fujiwara M; Sato S
    J Natl Cancer Inst; 1987 Jun; 78(6):1113-8. PubMed ID: 3295352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling.
    Meyer JS; Sufrin G; Martin SA
    J Urol; 1982 Dec; 128(6):1353-6. PubMed ID: 6185700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
    Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
    Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence.
    Ohoka H; Shinomiya H; Yokoyama M; Ochi K; Takeuchi M; Utsumi S
    Urol Res; 1985; 13(2):47-50. PubMed ID: 4012935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
    Brenner PC; Rettig WJ; Sanz-Moncasi MP; Reuter V; Aprikian A; Old LJ; Fair WR; Garin-Chesa P
    J Urol; 1995 May; 153(5):1575-9. PubMed ID: 7536270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
    Myers RB; Srivastava S; Grizzle WE
    J Urol; 1995 May; 153(5):1572-4. PubMed ID: 7714977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators.
    Spires SE; Banks ER; Davey DD; Jennings CD; Wood DP; Cibull ML
    Urology; 1994 May; 43(5):660-6. PubMed ID: 7909398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lectin binding to prostatic adenocarcinoma.
    Söderström KO
    Cancer; 1987 Oct; 60(8):1823-31. PubMed ID: 2443233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease.
    McClinton S; Miller ID; Eremin O
    Br J Cancer; 1990 Mar; 61(3):400-3. PubMed ID: 1691655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood group antigen expression in dysplasia and adenocarcinoma of the prostate.
    Perlman EJ; Epstein JI
    Am J Surg Pathol; 1990 Sep; 14(9):810-8. PubMed ID: 1697143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
    Guo Y; Sklar GN; Borkowski A; Kyprianou N
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2269-74. PubMed ID: 9815624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histochemical studies of epithelial cell glycoconjugates in atrophic, metaplastic, hyperplastic, and neoplastic canine prostate.
    Orgad U; Alroy J; Ucci A; Merk FB
    Lab Invest; 1984 Mar; 50(3):294-302. PubMed ID: 6199584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of prostate specific antigen in prostatic cancer.
    Guinan P; Bhatti R; Ray P
    J Urol; 1987 Apr; 137(4):686-9. PubMed ID: 2435927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines.
    Wolf MF; Koerner U; Schumacher K
    Cancer Res; 1986 Apr; 46(4 Pt 1):1779-82. PubMed ID: 2418954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate antigen: a new potential marker for prostatic cancer.
    Wang MC; Papsidero LD; Kuriyama M; Valenzuela LA; Murphy GP; Chu TM
    Prostate; 1981; 2(1):89-96. PubMed ID: 6169079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry.
    Yuan M; Itzkowitz SH; Boland CR; Kim YD; Tomita JT; Palekar A; Bennington JL; Trump BF; Kim YS
    Cancer Res; 1986 Sep; 46(9):4841-7. PubMed ID: 3731131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.